AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)

Asklepios BioPharmaceutical, Inc. announced that the European Commission has granted orphan drug designation for AB-1003 for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.